Strides Shasun gets DCGI approval to manufacture Hepatitis C drug
The drug will be marketed under the brand name ‘Virso’ in India and overseasBangalore-based Strides Shasun Ltd. on Monday announced that it has received DCGI (Drug Controller General of India) nod for manufacturing generic version of Sofosbuvir 400mg drug. The drug major entered into a licensing agreement with Gilead Sciences – a US-based biopharmaceutical company - to bring Hepatitis C cure to 91 developing countries. The product will be marketed under the brand name ‘Virso’ in India and overseas. “The high potency, high barrier to resistance, pan genotypic activity, one-daily dosage, good safety profile and the limited drug-drug interaction of Sofosbuvir make it a breakthrough drug in Hepatitis C treatment,” Strides Shasun said in a statement. The drug is used in the treatment of Hepatitis C and can have high cure rate of around 90%. It is estimated that about 170-185 million people are chronically infected with Hepatitis C virus across the world. In India, approximately 12-18 million people are infected with Hepatitis C virus. Strides Shasun Ltd. has 12 manufacturing facilities across three continents including six USFDA approved facilities.
December 21, 2015 | 03:15pm IST
to success.